MLchartDataset catalogue

CDK inhibitor AT7519

Term · Oncology and biomedicine · MLC-T-ONC-012435

An orally bioavailable small molecule with potential antineoplastic activity. AT7519M selectively binds to and inhibits cyclin dependent kinases (CDKs), which may result in cell cycle arrest, induction of apoptosis, and inhibition of tumor cell proliferation. CDKs are serine/threonine kinases involved in regulation of the cell cycle and may be overexpressed in some types of cancer cells.

Table 1. Record
IdentifierMLC-T-ONC-012435
FieldOncology and biomedicine
Synonymscyclin-dependent kinase inhibitor AT7519M
ReferencesNational Cancer Institute Thesaurus (CC BY 4.0)
Record as JSON
{
  "id": "MLC-T-ONC-012435",
  "term": "CDK inhibitor AT7519",
  "field": "Oncology and biomedicine",
  "definition": "An orally bioavailable small molecule with potential antineoplastic activity. AT7519M selectively binds to and inhibits cyclin dependent kinases (CDKs), which may result in cell cycle arrest, induction of apoptosis, and inhibition of tumor cell proliferation. CDKs are serine/threonine kinases involved in regulation of the cell cycle and may be overexpressed in some types of cancer cells.",
  "synonyms": [
    "cyclin-dependent kinase inhibitor AT7519M"
  ],
  "references": [
    "National Cancer Institute Thesaurus"
  ],
  "url": "https://mlchart.com/terminology/oncology/cdk-inhibitor-at7519/"
}

Record 4,460 of 17,717 in Oncology and biomedicine terminology (MLC-0111). Request the full dataset.